Prostate cancer cells use genetic and epigenetic mechanisms for progression to androgen independence

Genes Chromosomes and Cancer

Volumn 45, Issue 7, 2006, Pages 702-716

  Murillo, Horacio ^a,b   Schmidt, Lucy J ^a   Karter, Melissa ^c   Hafner, Kari A ^a   Kondo, Yasushi ^a   Ballman, Karla V ^a   Vasmatzis, George ^a,d   Jenkins, Robert B ^a   Tindall, Donald J ^a,b,e  

^a Mayo Clinic   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d MAYO CLINIC CANCER CENTER   (United States)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN;

ARTICLE; CANCER CELL CULTURE; CANCER GENETICS; CANCER GROWTH; CELL STRAIN LNCAP; CONTROLLED STUDY; CYTOGENETICS; EPIGENETICS; GENE EXPRESSION; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MICROARRAY ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER;

ANDROGENS; ANIMALS; CELL LINE, TUMOR; CHROMOSOME BANDING; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LOSS OF HETEROZYGOSITY; MALE; MICE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PROSTATIC NEOPLASMS; SPECTRAL KARYOTYPING;

EID: 33646575331     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20333     Document Type: Article

References (66)

1. Abdollahi A, Pisarcik D, Roberts D, Weinstein J, Cairns P, Hamilton TC. 2003. LOT1 (PLAGL1/ZAC1), the candidate tumor suppressor gene at chromosome 6q24-25, is epigenetically regulated in cancer. J Biol Chem 278:6041-6049.
2. Ballman KV, Grill DE, Oberg AL, Therneau TM. 2004. Faster cyclic loess: Normalizing RNA arrays via linear models. Bioinformatics 20:2778-2786.
3. Bilanges B, Varrault A, Basyuk E, Rodriguez C, Mazumdar A, Pantaloni C, Bockaert J, Theillet C, Spengler D, Journot L. 1999. Loss of expression of the candidate tumor suppressor gene ZAC in breast cancer cell lines and primary tumors. Oncogene 18:3979-3988.
4. Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein JI, Isaacs WB. 1990. Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci USA 87:8751-8755.
5. Chang GT, Blok LJ, Steenbeek M, Veldscholte J, van Weerden WM, van Steenbrugge GJ, Brinkmann AO. 1997. Differentially expressed genes in androgen-dependent and -independent prostate carcinomas. Cancer Res 57:4075-4081.
6. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB, Jensen RH. 1996. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 56:3091-3102.
7. Chu TM, Weir B, Wolfinger R, 2002. A systematic statistical linear modeling approach to oligonucleotide array experiments. Math Biosci 176:35-51.
8. Chung LW, Baseman A, Assikis V, Zhau HE. 2005. Molecular insights into prostate cancer progression: The missing link of tumor microenvironment. J Urol 173:10-20.
9. Chung LW, Chang SM, Bell C, Zhau HE, Ro JY, von Eschenbach AC. 1989. Co-inoculation of tumorigenic rat prostate mesenchymal cells with non-tumorigenic epithelial cells results in the development of carcinosarcoma in syngeneic and athymic animals. Int J Cancer 43:1179-1187.
10. Cooney KA, Wetzel JC, Consolino CM, Wojno KJ. 1996. Identification and characterization of proximal 6q deletions in prostate cancer. Cancer Res 56:4150-4153.
11. Craft N, Chhor C, Tran C, Belldegrun A, DeKernion J, Witte ON, Said J, Reiter RE, Sawyers CL. 1999. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res 59:5030-5036.
12. Cvetkovic D, Pisarcik D, Lee C, Hamilton TC, Abdollahi A. 2004. Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer. Gynecol Oncol 95:449-455.
13. Das K, Lau W, Sivaswaren C, Ph T, Fook-Chong S, Sl T, Cheng C. 2005. Chromosomal changes in prostate cancer: A fluorescence in situ hybridization study. Clin Genet 68:40-47.
14. Davies G, Jiang WG, Mason MD. 1998. E-cadherin and associated molecules in the invasion and progression of prostate cancer. Oncol Rep 5:1567-1576.
15. Dudoit S, Yang YH, Callow MJ, Speed TP. 2002. Statistical methods for identifying differentially expressed genes in replicated cDNA microarray experiments. Statistica Sinica 12:111-139.
16. Foster CS, Bostwick DG, Bonkhoff H, Damber JE, van der Kwast T, Montironi R, Sakr WA. 2000. Cellular and molecular pathology of prostate cancer precursors. Scand J Urol Nephrol Suppl 205:19-43.
17. Gleave M, Hsieh JT, Gao CA, von Eschenbach AC, Chung LW. 1991. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 51:3753-3761.
18. Glinsky GV, Krones-Herzig A, Glinskii AB, Gebauer G. 2003. Microarray analysis of xenograft-derived cancer cell lines representing multiple experimental models of human prostate cancer. Mol Carcinog 37:209-221.
19. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK, Sandberg AA. 1980. The LNCaP cell line-A new model for studies on human prostatic carcinoma. Prog Clin Biol Res 37:115-132.
20. Hyytinen ER, Thalmann GN, Zhau HE, Karhu R, Kallioniemi OP, Chung LW, Visakorpi T. 1997. Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model. Br J Cancer 75:190-195.
21. Igawa T, Lin FF, Lee MS, Karan D, Batra SK, Lin MF. 2002. Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate 50:222-235.
22. Jenkins R, Takahashi S, DeLacey K, Bergstralh E, Lieber M. 1998. Prognostic significance of allelic imbalance of chromosome arms 7q, 8p, 16q, and 18q in stage T3N0MO prostate cancer. Genes Chromosomes Cancer 21:131-143.
23. Joos S, Bergerheim US, Pan Y, Matsuyama H, Bentz M, du Manoir S, Lichter P. 1995. Mapping of chromosomal gains and losses in prostate cancer by comparative genomic hybridization. Genes Chromosomes Cancer 14:267-276.
24. Kasahara K, Taguchi T, Yamasaki I, Kamada M, Yuri K, Shuin T. 2002. Detection of genetic alterations in advanced prostate cancer by comparative genomic hybridization. Cancer Genet Cytogenet 137:59-63.
25. Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun A, Witte ON, Sawyers CL. 1997. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 3:402-408.
26. Konig JJ, Teubel W, Romijn JC, Schroder FH, Hagemeijer A. 1996. Gain and loss of chromosomes 1, 7, 8, 10, 18, and Y in 46 prostate cancers. Hum Pathol 27:720-727.
27. Konishi N, Nakamura M, Kishi M, Ishida E, Shimada K, Matsuyoshi S, Nagai H, Emi M. 2003. Genetic mapping of allelic loss on chromosome 6q within heterogeneous prostate carcinoma. Cancer Sci 94:764-768.
28. Kunimi K, Bergerheim US, Larsson IL, Ekman P, Collins VP. 1991. Allelotyping of human prostatic adenocarcinoma. Genomics 11:530-536.
29. Laitinen S, Karhu R, Sawyers CL, Vessella RL, Visakorpi T. 2002. Chromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization. Genes Chromosomes Cancer 35:66-73.
30. Law M, Jalal SM. 2000. M-FISH technique: How to set up and analyze. J Assoc Genet Technol 26:51-53.
31. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Pue J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R. 1997. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943-1947.
32. Li LC, Carroll PR, Dahiya R. 2005. Epigenetic changes in prostate cancer: Implication for diagnosis and treatment. J Natl Cancer Inst 97:103-115.
33. Lin B, White JT, Lu W, Xie T, Utleg AG, Yan X, Yi EC, Shannon P, Khrebtukova I, Lange PH, Goodlett DR, Zhou D, Vasicek TJ, Hood L. 2005. Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: A systems approach to disease. Cancer Res 65:3081-3091.
34. Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H. 2005. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 65:4218-4227.
35. Lund AH, van Lohuizen M. 2004. Epigenetics and cancer. Genes Dev 18:2315-2335.
36. Macville M, Schrock E, Padilla-Nash H, Keck C, Ghadimi BM, Zimonjic D, Popescu N, Ried T. 1999. Comprehensive and definitive molecular cytogenetic characterization of HeLa cells by spectral karyotyping. Cancer Res 59:141-150.
37. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML. 1992. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940-6944.
38. Mitelman F, editor. 1995. An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: Karger.
39. Murillo H, Huang H, Schmidt LJ, Smith DI, Tindall DJ. 2001. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 142:4795-4805.
40. Nelson JB, Carducci MA. 2000. Small bioactive peptides and cell surface peptidases in androgen-independent prostate cancer. Cancer Invest 18:87-96.
41. Pan Y, Kytola S, Farnebo F, Wang N, Lui WO, Nupponen N, Isola J, Visakorpi T, Bergerheim US, Larsson C. 1999. Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping. Cytogenet Cell Genet 87:225-232.
42. Papandreou CN, Usmani B, Geng Y, Bogenrieder T, Freeman R, Wilk S, Finstad CL, Reuter VE, Powell CT, Scheinberg D, Magill C, Scher HI, Albino AP, Nanus DM. 1998. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med 4:50-57.
43. Piras G, El Kharroubi A, Kozlov S, Escalante-Alcalde D, Hernandez L, Copeland NG, Gilbert DJ, Jenkins NA, Stewart CL. 2000. Zac1 (Lot1), a potential tumor suppressor gene, and the gene for ε-sarcoglycan are maternally imprinted genes: Identification by a subtractive screen of novel uniparental fibroblast lines. Mol Cell Biol 20:3308-3315.
44. Rennie P, Nelson CC. 1998. Epigenetic mechanisms for progression of prostate cancer. Cancer Metastasis Rev 17:104-109.
45. Schrock E, du Manoir S, Veldman T, Schoell B, Wienberg J, Ferguson-Smith MA, Ning Y, Ledbetter DH, Bar-Am I, Soenksen D, Garini Y, Ried T. 1996. Multicolor spectral karyotyping of human chromosomes. Science 273:494-497.
46. Shi XB, Ma AH, Tepper CG, Xia L, Gregg JP, Candour-Edwards R, Mack PC, Kung HJ, DeVere White RW. 2004. Molecular alterations associated with LNCaP cell progression to androgen independence. Prostate 60:257-271.
47. Sobel RE, Sadar MD. 2005a. Cell lines used in prostate cancer research: A compendium of old and new lines-Part 1. J Urol 173:342-359.
48. Sobel RE, Sadar MD. 2005b. Cell lines used in prostate cancer research: A compendium of old and new lines-Part 2. J Urol 173:360-372.
49. Srikantan V, Sesterhenn IA, Davis L, Hankins GR, Avallone FA, Livezey JR, Connelly R, Mostofi FK, McLeod DG, Moul JW, Chandrasekharappa SC, Srivastava S. 1999. Allelic loss on chromosome 6Q in primary prostate cancer. Int J Cancer 84:331-335.
50. St John MA, Tao W, Fei X, Fukumoto R, Carcangiu ML, Brownstein DG, Parlow AF, McGrath J, Xu T. 1999. Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. Nat Genet 21:182-186.
51. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV. 1997. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15:356-362.
52. Stephenson RA, Dinney CP, Gohji K, Ordonez NG, Killion JJ, Fidler IJ. 1992. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J Natl Cancer Inst 84:951-957.
53. Strefford JC, Lillington DM, Young BD, Oliver RT. 2001. The use of multicolor fluorescence technologies in the characterization of prostate carcinoma cell lines: A comparison of multiplex fluorescence in situ hybridization and spectral karyotyping data. Cancer Genet Cytogenet 124:112-121.
54. Thalmann GN, Sikes RA, Wu TT, Degeorges A, Chang SM, Ozen M, Pathak S, Chung LW. 2000. LNCaP progression model of human prostate cancer: Androgen-independence and osseous metastasis. Prostate 44:91-103.
55. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Monde JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. 2005. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644-648.
56. Trojan L, Schaaf A, Steidler A, Haak M, Thalmann G, Knoll T, Gretz N, Alken P, Michel MS. 2005. Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines. Anticancer Res 25:183-191.
57. van Bokhoven A, Caires A, Maria MD, Schulte AP, Lucia MS, Nordeen SK, Miller GJ, Varella-Garcia M. 2003. Spectral karyotype (SKY) analysis of human proscate carcinoma cell lines. Prostate 57:226-244.
58. van Dekken H, Alers JC, Damen IA, Vissers KJ, Krijtenburg PJ, Hoedemaeker RF, Wildhagen MF, Hop WC, van der Kwast TH, Tanke HJ, Schroder FH. 2003. Genetic evaluation of localized prostate cancer in a cohort of forty patients: Gain of distal 8q discriminates between progressors and nonprogressors. Lab Invest 83:789-796.
59. van Dekken H, Paris PL, Albertson DG, Alers JC, Andava A, Kowbel D, van der Kwast TH, Pinkel D, Schroder FH, Vissers KJ, Wildhagen MF, Collins C. 2004. Evaluation of genetic patterns in different tumor areas of intermediate-grade prostatic adenocarcinomas by high-resolution genomic array analysis. Genes Chromosomes Cancer 39:249-256.
60. van Duin M, van Marion R, Vissers K, Watson JE, van Weerden WM, Schroder FH, Hop WC, van der Kwast TH, Collins C, van Dekken H. 2005. High-resolution array comparative genomic hybridization of chromosome arm 8q: Evaluation of genetic progression markers for prostate cancer. Genes Chromosomes Cancer 44:438-449.
61. van Weerden WM, de Ridder CM, Verdaasdonk CL, Romijn JC, van der Kwast TH, Schroder FH, van Steenbrugge GJ. 1996. Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am J Pathol 149:1055-1062.
62. Verma RS, Manikal M, Conte RA, Codec CJ. 1999. Chromosomal basis of adenocarcinoma of the prostate. Cancer Invest 17:441-447.
63. Visakorpi T, Kallioniemi AH, Syvanen AC, Hyytinen ER, Karhu R, Tammela T, Isola JJ, Kallioniemi OP. 1995. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 55:342-347.
64. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J. 1998. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 58:2720-2723.
65. Vocke CD, Pozzatti RO, Bostwick DG, Florence CD, Jennings SB, Strup SE, Duray PH, Liotta LA, Emmert-Buck MR, Linehan WM. 1996. Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8pl2-21. Cancer Res 56:2411-2416.
66. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW, Isaacs WB, Sawyers CL. 1998. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 95:5246-5250.